Neovacs S.A Enterprise value
What is the Enterprise value of Neovacs S.A?
The Enterprise value of Neovacs S.A. is -$31.13
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with enterprise value similar to Neovacs S.A
- TDb Split has Enterprise value of -$31.63
- Xinyuan Property Management Service (Cayman) has Enterprise value of -$31.48
- Playmates Toys has Enterprise value of -$31.42
- Capital VC has Enterprise value of -$31.41
- Forgame has Enterprise value of -$31.29
- Ellex Medical Lasers has Enterprise value of -$31.28
- Neovacs S.A has Enterprise value of -$31.13
- Ayala Pharmaceuticals has Enterprise value of -$31.07
- Gracell Biotechnologies has Enterprise value of -$31.05
- Graybug Vision has Enterprise value of -$31.03
- Ourgame International has Enterprise value of -$30.97
- Agora has Enterprise value of -$30.92
- Canopy Rivers has Enterprise value of -$30.42